Dyskinesia, Drug-Induced Clinical Trial
Official title:
Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study
The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia
Objective:A few case reports on the use of aripiprazole in neuroleptic-induced tardive
dyskinesia have demonstrated positive effects. However its effectiveness in treatment of TD
was still inconclusive. The aim of the present study was to investigate the efficacy of
aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia.
Method: Subjects with pre-existing neuroleptic-induced tardive dyskinesia were chosen from
Taoyuan psychiatric center. Patients recruited would be treated with aripiprazole for
cross-titration with previous antipsychotics in 8 weeks. We use AIMS, SAS, & BAS to assess
the severity of TF and EPS. We record subjects' age, sex, and other factors which have
influence at the treatment response. Subjects are assessed every two weeks in the first
month and then monthly until six months.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05116813 -
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT03987750 -
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
|
Phase 3 | |
| Completed |
NCT01173731 -
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
|
Phase 2 | |
| Recruiting |
NCT04064294 -
Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
|
||
| Terminated |
NCT00686699 -
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
|
Phase 2 | |
| Completed |
NCT00255879 -
Movement Disorders Caused by Antipsychotic Drugs in Older Patients
|
Phase 1 | |
| Recruiting |
NCT04857359 -
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
|
Phase 2/Phase 3 | |
| Completed |
NCT03354455 -
Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease
|
N/A |